Chaudhary Arpana Sagwal
Intellectual Property Consultant, Life Sciences, CA 94597, USA.
Acta Pharm Sin B. 2016 Nov;6(6):552-556. doi: 10.1016/j.apsb.2016.06.004. Epub 2016 Jul 15.
Data from across the world have shown an overall decline in the antibiotic pipeline and continually rising resistance to all first-line and last-resort antibiotics. The gaps in our knowledge of existing prevalence and mechanisms of antibiotic resistance (ABR) are all too well known. Several decades of antibiotic abuse in humans, animals, and agricultural practices have created health emergency situations and huge socio-economic impact. This paper discusses key findings of the studies conducted by several national and international collaborative organizations on the current state of affairs in ABR. Alongside, a brief overview of the antibacterial agents׳ discovery in recent years approved by the US FDA is discussed.
来自世界各地的数据显示,抗生素研发渠道总体呈下降趋势,对所有一线和最后手段抗生素的耐药性持续上升。我们对抗生素耐药性(ABR)现有流行情况和机制的了解存在诸多差距,这是众所周知的。几十年来,抗生素在人类、动物和农业实践中的滥用造成了健康紧急情况和巨大的社会经济影响。本文讨论了几个国家和国际合作组织就ABR现状所开展研究的主要发现。同时,还讨论了近年来美国食品药品监督管理局(US FDA)批准的抗菌药物的简要概况。